康方生物-B(09926.HK):AK112 Ia期臨牀研究階段性數據在2020中國腫瘤免疫治療會議上發佈
格隆匯 11 月 2日丨康方生物-B(09926.HK)發佈公告,公司核心自主研發的新藥PD-1/VEGF雙特異性抗體(研發代號:AK112)Ia期臨牀研究階段性數據已在2020中國腫瘤免疫治療會議上發佈。
目前AK112已經在澳洲和中國開展Ia期臨牀研究,最初劑量遞增階段的臨牀研究結果令人鼓舞。該研究的結果顯示,在有至少經歷過一次腫瘤評估並對PD-1抑制劑不敏感或接受過PD-1抑制劑治療的11例晚期實體瘤患者中,共有4例達到了緩解(客觀緩解率(ORR):36 %),共7例腫瘤縮小且疾病穩定(疾病控制率(DCR):64%)。
公告表示,這表明PD-1/VEGF雙抗(AK112)有潛力成為突破性的療法,為PD-1抑制劑不敏感或接受過PD-1抑制劑治療的病人帶來新的希望。 PD-1抑制劑與VEGF抑制劑的聯合療法已在多個瘤種(如腎細胞癌、非小細胞肺癌和肝細胞癌)中展現出顯著的療效。AK112是公司自主研發、全球首個進入臨牀研究的PD-1/VEGF雙特異性抗體。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.